Cardiovascular Disease-Related Candidate Polymorphisms in the Hutterites

(from Newman et al. 2004)

721 Hutterites were genotyped for 65 biallelic polymorphisms in 36 genes using a linear array system developed by Roche Molecular Systems (Alameda, CA). These polymorphisms were selected as candidate markers for cardiovascular disease based on published reports. Allele frequencies are based on best-linear unbiased estimates that take into account the relatedness between individuals (McPeek et al. 2004). All polymorphisms are written with the higher frequency allele first.

Table 1. Allele Frequencies
 
Gene Polymorphism
rs#
Location
Minor Allele Frequency
Standard Deviation
ACE intron 16 ins/del
1799752
17q23
0.301
0.087
ADD1 gly460trp
4961
4p16.2
0.126
0.063
ADRB2 gly16arg
1042713
5q32
0.313
0.088
ADRB2 gln27glu
1042714
5q32
0.486
0.094
ADRB3 trp64arg
4994
8p11.22
0.027
0.031
AGT thr235met
699
1q42.13
0.462
0.095
AGTR1 1166 A/C
5186
3q24
0.302
0.087
APOA4 thr347ser
675
11q23.3
0.351
0.091
APOA4 gln360his
5110
11q23.3
0
-
APOB thr71ile
1367117
2p24
0.188
0.074
APOB arg3500gln
5742904
2p24
0
-
APOC3 -641 C/A
2542052
11q23.3
0.485
0.095
APOC3 -482 C/T
2854117
11q23.3
0.279
0.085
APOC3 -455 T/C
2854116
11q23.3
0.483
0.095
APOC3 1100 C/T
4520
11q23.3
0.321
0.089
APOC3 3175 C/G
5128
11q23.3
0.139
0.066
APOC3 3206 T/G
4225
11q23.3
0.334
0.090
APOE cys112arg
429358
19q13
0.139
0.066
APOE arg158cys
7412
19q13
0.018
0.025
CBS ile278thr,68-bp ins*
5742905
21q22.3
0.040
0.037
CETP -631 C/A
1800776
16q21
0.006
0.015
CETP -629 A/C
1800775
16q21
0.432
0.099
CETP ile405val
5882
16q21
0.376
0.092
CETP asp442gly
2303790
16q21
0
-
CETP intron 14 G+1A
-
16q21
0
-
CETP intron 14 +3 ins T
-
16q21
0
-
F2 20210 G/A
1799963
11p11.1
0
-
F5 arg506gln
6025
1q23
0.054
0.043
F7 arg353gln
6046
13q34
0.272
0.084
F7 -323 del/ins
5742910
13q34
0.274
0.085
FGB -455 G/A
1800790
4q28
0.217
0.078
GNB3 825 C/T
5443
12p13
0.302
0.087
ICAM1 gly214arg
1799969
19p13
0.113
0.060
ITGA2 873 G/A
1062535
5q11.2
0.453
0.094
ITGB3 leu33pro
5918
17q21
0.174
0.072
LDLR NcoI+/-
5742911
19p13.2
0.300
0.087
LIPC -480 C/T
1800588
5q21
0.196
0.076
LPA +93 C/T
1652503
6q27
0.123
0.063
LPA +121 G/A
1800769
6q27
0.121
0.062
LPL -93 T/G
1800590
8p22
0
-
LPL asp9asn
1801177
8p22
0
-
LPL asn291ser
268
8p22
0
-
LPL ser447term
328
8p22
0.113
0.060
LTA thr26asn
1041981
6p21.3
0.172
0.072
MMP3 -1171 A5/A6
3025058
11q22
0.329
0.090
MTHFR 677 C/T
1801133
1p36.3
0.390
0.093
NOS3 -922 A/G
1800779
7q36
0.469
0.094
NOS3 -690 C/T
3918226
7q36
0.076
0.051
NOS3 asp298glu
1799983
7q36
0.493
0.094
NPPA 664 G/A
5063
1p36.2
0
-
NPPA 2238 T/C
5065
1p36.2
0.065
0.047
PAI1 -675 G5/G4
1799768
7q22
0.368
0.092
PAI1 11053 T/G
7242
7q22
0.312
0.088
PON1 leu55met
3202100
7q21
0.252
0.083
PON1 gln192arg
662
7q21
0.318
0.088
PON2 ser311cys
7493
7q21
0.220
0.079
PPARG pro12ala
1801282
3p25
0.139
0.066
SCNN1A trp493arg
5742912
12p13
0.060
0.045
SCNN1A ala663thr
2228576
12p13
0.327
0.089
SELE leu554phe
5355
1q23
0
-
SELE ser128arg
5361
1q23
0.054
0.043
TNF -376 G/A
1800750
6p21.3
0.026
0.030
TNF -308 G/A
1800629
6p21.3
0.025
0.029
TNF -244 G/A
673
6p21.3
0
-
TNF -238 G/A
361525
6p21.3
0.121
0.062

*Flanking sequence in this record is from cDNA. Linear array assay cannot distinguish between heterozygous and homozygous carriers of the insertion.
 
 

Tests of Association

To test for association with quantitative traits (triglycerides [TG], LDL, HDL, Lp(a), SBP, DBP), we used the general two-allele model (GTAM) test, which takes into account the relatedness between all individuals in our sample and assesses the fit of a quantitative trait to various genetic models (dominant, recessive, additive) (Abney et al. 2002). In these analyses, age and gender were included as covariates.

In addition, we tested these alleles for association with lipid levels and hypertension (HTN) using two case-control association tests (corrected chi-squared and quasi-likelihood) that take into account the relatedness between all the individuals in the sample (Bourgain et al. 2003). The cases were individuals in our sample in the highest quartile for LDL, Lp(a) and TG and the lowest quartile for HDL, while the controls were the individuals in the lowest quartile for LDL, Lp(a) and TG and the highest quartile for HDL, after adjusting for age and gender; the cases for HTN were taking antihypertensive medication, stage 1 or higher hypertension as defined by the World Health Organization-International Society of Hypertension (1999), or children with high blood pressure as defined by Williams et al. (2002) and the controls for HTN were age and gender matched normotensive individuals for all cases under age 40, plus all normotensive adults over age 40.

Lipid levels were determined by measurement of blood samples drawn after an overnight fast. All associations with p <0.05 for at least one test of association are included in tables 2-6. For the GTAM results, direction indicates whether increasing (+) or decreasing (-) phenotypic values were associated with an increasing number of copies of the indicated allele. For the case-control tests, the allele that has higher frequency in the cases is listed. Abbreviations: GTAM = general two-allele model, na = not applicable, HT = heterozygote, Chi2 = corrected chi-squared method, QL = quasi-likelihood method, SBP = systolic blood pressure, DBP = diastolic blood pressure, HTN = hypertension

Table 2. Serum Triglycerides (TG) Levels. TG was measured on 485 Hutterites age 14 and older.
 
GTAM Results
Case:Control Results
Gene Polymorphism
Allele
Direction
Model
p-value
Allele
Chi2 p-value
QL p-value
APOC3 -641 A/C
A
+
dominant
0.010
A
0.078
0.088
APOC3 -482 C/T
C
-
additive/recessive
0.016
C
0.040
>0.10
APOC3 -455 T/C
T
-
additive/recessive
0.013
C
0.063
>0.10
APOC3 1100 C/T
C
-
additive
>0.10
T
>0.10
0.036
APOC3 3175 C/G
G
+
dominant
0.000093
G
0.0063
0.000016
APOC3 3206 T/G
G
+
dominant
0.047
G
>0.10
0.0065
CETP -631/-629 haplotype
CA
-
recessive
0.045
CC
>0.10
>0.10
ICAM1 gly214arg
arg
+
additive
0.032
arg
0.0054
0.096
PON2 ser311cys
na
na
HT lowest
>0.10
ser
0.042
>0.10
SCNN1A ala663thr
ala
+
dominant
0.048
ala
>0.10
>0.10
SELE ser128arg
arg
+
additive
>0.10
arg
0.054
>0.10

 

Table 3. Serum LDL Levels. LDL-cholesterol levels were determined for 452 Hutterites age 14 and older.
 
GTAM Results
Case:Control Results
Gene Polymorphism
Allele
Direction
Model
p-value
Allele
Chi2 p-value
QL p-value
AGTR1 1166 A/C
C
-
recessive
0.0064
A
0.0025
0.013
APOC3 1100 C/T
T
-
additive
>0.10
C
0.042
>0.10
APOC3 3206 T/G
G
-
additive
>0.10
T
0.026
>0.10
APOE haplotype
E2
-
additive
0.0010
E4
0.057
0.000060
FGB -455 G/A
Na
na
HT highest
>0.10
A
>0.10
0.025
LDLR NcoI+/- (A/G)
-
-
additive
0.063
+
0.0045
0.00022
LTA thr26asn
na
na
HT lowest
0.0081
thr
0.012
0.0070
NPPA 2238 T/C
Na
na
HT lowest
>0.10
T
0.039
>0.10

 

Table 4. Serum HDL Levels. HDL-cholesterol levels were measured on 485 Hutterites age 14 and older.
 
GTAM Results
Case:Control Results
Gene Polymorphism
Allele
Direction
Model
p-value
Allele
Chi2 p-value
QL p-value
AGTR1 1166 A/C
C
+
additive
>0.10
A
0.032
0.096
APOC3 -641 A/C
na
na
HT lowest
0.023
A
>0.10
>0.10
APOC3 -455 T/C
na
na
HT lowest
0.027
C
>0.10
>0.10
APOC3 3175 C/G
na
na
HT lowest
>0.10
G
0.078
0.042
CETP -631/-629 haplotype
CA
+
additive
0.000013
CC
0.00015
0.000039
ICAM1 gly214arg
gly
+
additive/recessive
>0.10
arg
0.0056
>0.10
PON2 ser311cys
na
na
HT highest
0.021
ser
0.0091
0.020
SCNN1A trp493arg
arg
-
additive
0.058
arg
0.021
0.070
SELE ser128arg
arg
-
additive
0.041
arg
0.037
0.019

 

Table 5. Serum Lipoprotein(a) Levels. Lp(a) levels were determined for 374 Hutterites age 14 and older.
 
GTAM Results
Case:Control Results
Gene Polymorphism
Allele
Direction
Model
p-value
Allele
Chi2 p-value
QL p-value
APOB thr71ile
thr
-
additive/recessive
0.019
ile
>0.10
0.026
CETP ile405val
val
+
additive/recessive
0.048
val
>0.10
>0.10
F7 arg353gln
arg
-
additive
0.079
gln
0.012
0.086
F7 -323 del/ins
ins
+
additive
0.067
ins
0.0037
0.027
FGB -455 G/A
A
-
additive
0.043
G
0.013
0.039
ITGB3 leu33pro
pro
+
dominant
>0.10
pro
0.011
>0.10
LPA 93 C/T
T
+
additive
0.000000029
T
0.074
0.00029
NOS3 -690 C/T
T
-
additive
>0.10
A
0.038
0.070
SELE ser128arg
ser
+
dominant
0.038
arg
0.027
>0.10

 

Table 6. Blood Pressure. Blood pressure was measured on 623 Hutterites age 5 and older.
 
GTAM Results (SBP)
GTAM Results (DBP)
Case:Control Results (HTN)
Gene Polymorphism
Allele
Direction
Model
p-value
Allele
Direction
Model
p-value
Allele
Chi2 p-value
QL p-value
ACE intron 16 ins/del
ins
+
additive
0.0026
ins
+
additive
>0.10
del
>0.10
>0.10
AGT thr235met
met
-
additive
0.027
met
-
additive
0.037
thr
0.050
>0.10
FGB -455 G/A
G
+
additive
0.015
A
-
additive
0.058
G
>0.10
>0.10
LIPC -480 C/T
na
na
HT highest
>0.10
T
+
additive
0.0022
T
0.0048
0.0090
LTA thr26asn
asn
+
additive/recessive
>0.10
asn
+
recessive
0.039
asn
0.011
0.033
PON2 ser311cys
na
na
HT lowest
0.042
na
na
HT lowest
>0.10
ser
>0.10
>0.10
TNF -308 G/A
G
-
additive
>0.10
G
-
additive
0.074
A
0.030
0.013

 

References

Abney M, Ober C, McPeek MS (2002) Quantitative-trait homozygosity and association mapping and empirical genomewide significance in large, complex pedigrees: fasting serum- insulin level in the hutterites. Am J Hum Genet 70:920-934 PDF

Bourgain C, Hoffjan S, Nicolae R, Newman DL, Steiner L, Reynolds R, Walker K, et al (2003) Novel case-control test in a founder population identifies P-selectin as an atopy susceptibility locus. Am J Hum Genet 73:612-626 PDF

McPeek MS, Wu X, Ober C (2004) Best linear unbiased allele-frequency estimation in complex pedigrees. Biometrics 60:in press

Newman DL, Hoffjan S, Bourgain C, Abney M, Nicolae RI, Profits EP, Grow MA, et al (2004) Are common disease susceptibility alleles the same in outbred and founder populations? Eur J Hum Genet, in press

Williams CL, Hayman LL, Daniels SR, Robinson TN, Steinberger J, Paridon S, Bazzarre T (2002) Cardiovascular health in childhood: A statement for health professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 106:143-160

World Health Organization-International Society of Hypertension (1999) 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 17:151-183